{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:22:49Z","timestamp":1778692969029,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T00:00:00Z","timestamp":1498003200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s10067-017-3725-3","type":"journal-article","created":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T18:29:02Z","timestamp":1497983342000},"page":"1715-1720","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis"],"prefix":"10.1007","volume":"36","author":[{"given":"Ashit","family":"Syngle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudeep","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inderjeet","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Syngle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijaita","family":"Syngle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,21]]},"reference":[{"key":"3725_CR1","first-page":"105","volume":"2006","author":"A Syngle","year":"2006","unstructured":"Syngle A (2006) Arthritis and its treatment. In Rattan S, Kassem M, editiors Prevention and treatment of age-related diseases. The Netherlands. Spring 2006:105\u2013132","journal-title":"Spring"},{"issue":"suppl 4","key":"3725_CR2","doi-asserted-by":"crossref","first-page":"iv14","DOI":"10.1093\/rheumatology\/kei055","volume":"44","author":"D Symmons","year":"2005","unstructured":"Symmons D (2005) Looking back: rheumatoid arthritis-aetiology, occurrence and mortality. Rheumatology 44(suppl 4):iv14\u2013iiv7","journal-title":"Rheumatology"},{"issue":"4","key":"3725_CR3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF00301258","volume":"13","author":"A Malaviya","year":"1993","unstructured":"Malaviya A, Kapoor S, Singh R, Kumar A, Pande I (1993) Prevalence of rheumatoid arthritis in the adult Indian population. Rheumatol Int 13(4):131\u2013134","journal-title":"Rheumatol Int"},{"issue":"1","key":"3725_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC et al (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68(1):1\u201326","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"3725_CR5","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/BOR.0b013e3280be58ee","volume":"19","author":"A Kavanaugh","year":"2007","unstructured":"Kavanaugh A (2007) Economic issues with new rheumatologic therapeutics. Curr Opin Rheumatol 19(3):272\u2013276","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"3725_CR6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/art.1780380305","volume":"38","author":"MJ Prashker","year":"1995","unstructured":"Prashker MJ, Meenan RF (1995) The total costs of drug therapy for rheumatoid arthritis. Arthritis Rheumatol 38(3):318\u2013325","journal-title":"Arthritis Rheumatol"},{"key":"3725_CR7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0049-0172(96)80016-3","volume":"25","author":"A Kavanaugh","year":"1996","unstructured":"Kavanaugh A, Heudebert G, Cush J, Jain R (1996) Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): a decision analysis model. Semin Arthritis Rheum 25:297\u2013307","journal-title":"Semin Arthritis Rheum"},{"key":"3725_CR8","first-page":"609","volume":"23","author":"A Anis","year":"1996","unstructured":"Anis A, Tugwell P, Wells G, Stewart D (1996) A cost effectiveness analysis of cyclosporine in rheumatoid arthritis. J Rheumatol 23:609\u2013613","journal-title":"J Rheumatol"},{"issue":"9","key":"3725_CR9","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2165\/00019053-200624090-00005","volume":"24","author":"E Akobundu","year":"2006","unstructured":"Akobundu E, Ju J, Blatt L, Mullins CD (2006) Cost-of-illness studies. PharmacoEconomics 24(9):869\u2013890","journal-title":"PharmacoEconomics"},{"issue":"3","key":"3725_CR10","first-page":"148","volume":"5","author":"V Shini","year":"2010","unstructured":"Shini V, Aboobacker S, Pahuja S, Revikumar K, Bhasi R (2010) Pharmacoeconomic study of DMARDs in the management of rheumatoid arthritis. Int J Pharm Sci Rev Res 5(3):148\u2013154","journal-title":"Int J Pharm Sci Rev Res"},{"issue":"1","key":"3725_CR11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.9734\/BJPR\/2013\/2229","volume":"3","author":"SR Gawde","year":"2013","unstructured":"Gawde SR, Shetty YC, Merchant S, Kulkarni UJ, Nadkar MY (2013) Drug utilization pattern and cost analysis in rheumatoid arthritis patients\u2014a cross-sectional study in tertiary care hospital, Mumbai. British Journal of Pharmaceutical Research 3(1):37\u201345","journal-title":"British Journal of Pharmaceutical Research"},{"issue":"11","key":"3725_CR12","first-page":"1305","volume":"4","author":"V Alex","year":"2015","unstructured":"Alex V, Cheruvallikattil S, Abraham S, Varghese B (2015) Cost of illness of rheumatoid arthritis in south India. World Journal of Pharmaceutical Research 4(11):1305\u20131315","journal-title":"World Journal of Pharmaceutical Research"},{"issue":"9","key":"3725_CR13","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569\u20132581","journal-title":"Arthritis Rheum"},{"key":"3725_CR14","first-page":"43","volume":"12","author":"A Chopra","year":"2004","unstructured":"Chopra A (2004) Rheumatology: made in India (Camps, COPCORD, HLA, Ayurveda, HAQ, WOMAC and drug trials). J Indian Rheum Assoc 12:43\u201353","journal-title":"J Indian Rheum Assoc"},{"key":"3725_CR15","unstructured":"Revikumar KG, Miglani BD (2009) A text book of pharmacy practice, 1st Ed, Vol 1, Career Publications, India, 2009, 447\u201356"},{"issue":"1","key":"3725_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3923\/rjpharm.2011.1.3","volume":"5","author":"S Prajapati","year":"2011","unstructured":"Prajapati S, Sahu VK, Tripathy S (2011) ECHO model for rheumatoid arthritis. The Pharm Res 5(1):1\u201311","journal-title":"The Pharm Res"},{"key":"3725_CR17","volume-title":"Primer on the rheumatic disease","author":"J Goronzy","year":"1997","unstructured":"Goronzy J, Cornelia M (1997) Rheumatoid arthritis epidemiology, pathology and pathogenesis. In: Klippel JH, Wehand CM, Wortmann RL (eds) Primer on the rheumatic disease, 11th edn. William M, Georgia","edition":"11th"},{"issue":"1","key":"3725_CR18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3","volume":"43","author":"GA Schellekens","year":"2000","unstructured":"Schellekens GA, Visser H, De Jong BA, Van Den Hoogen FH, Hazes JM, Breedveld FC et al (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43(1):155\u2013163","journal-title":"Arthritis Rheum"},{"issue":"7","key":"3725_CR19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/1756-185X.12754","volume":"18","author":"CS Lau","year":"2015","unstructured":"Lau CS, Chia F, Harrison A, Hsieh TY, Jain R, Jung SM et al (2015) APLAR rheumatoid arthritis treatment recommendations. Int J Rheum Dis 18(7):685\u2013713","journal-title":"Int J Rheum Dis"},{"key":"3725_CR20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G et al (2010) Treat-to-target: rationale and strategies. Ann Rheum Dis 69:631\u2013637","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3725_CR21","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4103\/0250-474X.33148","volume":"69","author":"AV Sukhpreet","year":"2007","unstructured":"Sukhpreet AV, Tiwari P (2007) Treatment and monitoring costs in rheumatoid arthritis: preliminary results from an Indian setting. Indian J Pharm Sci 69(2):226\u2013231","journal-title":"Indian J Pharm Sci"},{"issue":"7","key":"3725_CR22","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/rheumatology\/ker014","volume":"50","author":"TY Zhu","year":"2011","unstructured":"Zhu TY, Tam LS, Li EK (2011) Societal costs of rheumatoid arthritis in Hong Kong: a prevalence-based cost-of-illness study. Rheumatology (Oxford) 50(7):1293\u20131301","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"3725_CR23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3109\/s10165-009-0236-3","volume":"20","author":"E Tanaka","year":"2010","unstructured":"Tanaka E, Inoue E, Mannalithara A, Bennett M, Kamitsuji S, Taniguchi A et al (2010) Medical care costs of patients with rheumatoid arthritis during the prebiologics period in Japan: a large prospective observational cohort study. Mod Rheumatol 20(1):46\u201353","journal-title":"Mod Rheumatol"},{"issue":"1","key":"3725_CR24","first-page":"57","volume":"34","author":"M Osiri","year":"2007","unstructured":"Osiri M, Maetzel A, Tugwell P (2007) The economic burden of rheumatoid arthritis in a developing nation: results from a one-year prospective cohort study in Thailand. J Rheumatol 34(1):57\u201363","journal-title":"J Rheumatol"},{"key":"3725_CR25","first-page":"S118","volume":"27","author":"LC Franke","year":"2009","unstructured":"Franke LC, Ament AJ, van de Laar MA, Boonen A, Severens JL (2009) Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 27:S118\u2013S123","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"3725_CR26","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/1529-0131(199906)42:6<1209::AID-ANR18>3.0.CO;2-M","volume":"42","author":"E Yelin","year":"1999","unstructured":"Yelin E, Wanke LA (1999) An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 42(6):1209\u20131218","journal-title":"Arthritis Rheum"},{"issue":"10","key":"3725_CR27","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1002\/art.11439","volume":"48","author":"K Michaud","year":"2003","unstructured":"Michaud K, Messer J, Choi HK, Wolfe F (2003) Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527. Arthritis Rheum 48(10):2750\u20132762","journal-title":"Arthritis Rheum"},{"issue":"10","key":"3725_CR28","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/rheumatology\/37.10.1102","volume":"37","author":"AC Verhoeven","year":"1998","unstructured":"Verhoeven AC, Bibo JC, Boers M, Engel GL, van der Linden S (1998) Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatie therapie Bij Reumatoide Artritis. Br J Rheumatol 37(10):1102\u20131109","journal-title":"Br J Rheumatol"},{"key":"3725_CR29","first-page":"304","volume":"8","author":"HK Choi","year":"2000","unstructured":"Choi HK, Seeger JD, Kuntz KM (2000) Cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 8:304\u2013310","journal-title":"Arthritis Rheum"},{"issue":"11","key":"3725_CR30","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/acr.21755","volume":"64","author":"AA Kawatkar","year":"2012","unstructured":"Kawatkar AA, Jacobsen SJ, Levy GD et al (2012) Direct medical expenditure with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey. Arthritis Care Res 64(11):1649\u20131656","journal-title":"Arthritis Care Res"},{"key":"3725_CR31","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/rheumatology\/39.1.28","volume":"39","author":"NJ Cooper","year":"2000","unstructured":"Cooper NJ (2000) Economic burden of rheumatoid arthritis: a systemic review. Rheumatology 39:28\u201333","journal-title":"Rheumatology"},{"key":"3725_CR32","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/ard.61.9.818","volume":"61","author":"HM Lapsley","year":"2002","unstructured":"Lapsley HM, March JM, Tribe KL, Cross MJ, Courtenay BG, Brooks PM (2002) Living with rheumatoid arthritis: expenditures, health status, and social impact on patients. Ann Rheum Dis 61:818\u2013821","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-017-3725-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3725-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3725-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T07:29:58Z","timestamp":1569482998000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-017-3725-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,21]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["3725"],"URL":"https:\/\/doi.org\/10.1007\/s10067-017-3725-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,21]]}}}